Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation.

Clinical advances in hematology & oncology : H&O - 1 Aug 2021

Bekaii-Saab Tanios S

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Camptothecin
Fluorouracil
Leucovorin
Organoplatinum Compounds
Phenylurea Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35289786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation.PMID 35289786Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.Semantic proximity Read ↗

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).Semantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.Semantic proximity Read ↗

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity Read ↗

[Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer].Semantic proximity Read ↗

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Semantic proximity Read ↗

Cases in the management of metastatic colorectal cancer: sequencing therapies in a patient with the BRAF V600E mutation.Semantic proximity Read ↗

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.Semantic proximity Read ↗

Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.